The Champalimaud Foundation Hemato-oncology Unit has a new range of transplant solutions.
This advance is related to the possibility of processing, storing and distributing peripheral blood hematopoietic progenitors by the company Crioestaminal (specialized in stem cell cryopreservation). These “progenitors” are stem cells that are found in the bloodstream and have the ability to generate all types of blood cells.
In a statement, Paulo Lúcio, director of the Champalimaud Foundation’s Hemato-Oncology Unit, stressed that the “Champalimaud Foundation’s hematopoietic progenitor autotransplantation program, which began at the end of 2024, is progressing at a good pace and without any hiccups. We have already carried out nine transplants, all of which were successful and without any complications.”
This is also the first partnership between private entities for autologous transplantation – which is a procedure in which the patient’s own stem cells are harvested and then reinfused after treatment, for example, chemotherapy.
Quoted in the statement sent to the newsrooms, Mónica Brito, CEO of Crioestaminal, emphasizes that “this specialized service represents a significant advance in medicine in Portugal”.
The post Transplants with new stem cell options appeared first on Veritas News.
